Mr. Andre Larente reports

DIAGNOS TO EXTEND THE EXERCISE PERIOD OF STOCK WARRANTS

Diagnos Inc. intends to amend the expiry date of 6,715,369 stock warrants from Aug. 5, 2026, to June 5, 2027. The warrants were issued as part of a non-brokered private placement of units initially announced on Feb. 5, 2025, and on Feb. 14, 2025.

All other provisions of the warrants, such as the exercise price of 40 cents per common share, shall remain unchanged and fully in effect during the extended exercise period.

The amendment remains subject to the TSX Venture Exchange acceptance as well as execution of formal documentation.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.